[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Orexo Ab Ord (ORXOF)

Orexo Ab Ord (ORXOF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Invitation & Agenda: Orexo R&D Day on March 24

UPPSALA, Sweden , March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event...

ORXOY : 2.0000 (+11.10%)
ORXOF : 2.1000 (-6.25%)
Orexo changes the organizational structure and management team to increase focus on development of new products

UPPSALA, Sweden , March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) , today announces changes to its organizational structure and management team. The changes are a result...

ORXOY : 2.0000 (+11.10%)
ORXOF : 2.1000 (-6.25%)
Orexo AB to Present Q3 2025 Interim Report and Project Updates

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Orexo AB...

ORXOF : 2.1000 (-6.25%)
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

UPPSALA, Sweden , Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide...

ORXOY : 2.0000 (+11.10%)
ORXOF : 2.1000 (-6.25%)

Barchart Exclusives

This Blue-Chip Dividend Stock Just Boosted Its Payout by 200% to $0.60 Per Share
DuPont de Nemours raised its quarterly dividend by 200% to $0.60 per share, signaling strong confidence in its cash generation and future outlook amid a challenging industrial environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.